Multivariable Cox proportional hazards regression models for overall survival limited to patients who underwent LND with at least 10 pelvic nodes and at least one para-aortic node removed stratified by histotype
| Variable | Level | Histology 1 | Histology 2 | ||
| Multivariable hazard ratio (95% CI)* | P value | Multivariable hazard ratio (95% CI)* | P value | ||
| LN surgery | ALND only | 1.0 reference | 1.0 reference | ||
| SLN biopsy only | 0.87 (0.64 to 1.19) | 0.386 | 1.29 (0.87 to 1.91) | 0.209 | |
| SLN and ALND | 1.11 (0.75 to 1.63) | 0.601 | 0.97 (0.69 to 1.37) | 0.858 | |
| Age | Per 10 years | 1.92 (1.52 to 2.42) | <0.001 | 1.43 (1.32 to 1.56) | <0.001 |
| Race | White | 1.0 reference | 1.0 reference | ||
| Black | 1.46 (1.19 to 1.79) | <0.001 | 1.53 (1.32 to 1.77) | <0.001 | |
| Other | 0.97 (0.72 to 1.31) | 0.856 | 1.0 (0.75 to 1.33) | 0.976 | |
| Unknown | 1.24 (0.68 to 2.26) | 0.476 | 0.81 (0.43 to 1.51) | 0.507 | |
| Charlson-Deyo score | 0 | 1.0 reference | 1.0 reference | ||
| 1 | 1.26 (1.17 to 1.37) | <0.001 | 1.15 (1.01 to 1.32) | 0.036 | |
| ≥2 | 1.97 (1.75 to 2.21) | <0.001 | 1.32 (1.02 to 1.70) | 0.032 | |
| Insurance status | Private insurance | 1.0 reference | 1.0 reference | ||
| Not insured | 1.76 (1.29 to 2.41) | <0.001 | 0.97 (0.69 to 1.38) | 0.879 | |
| Medicaid | 1.62 (1.23 to 2.13) | <0.001 | 1.18 (0.90 to 1.56) | 0.236 | |
| Medicare | 1.27 (1.08 to 1.48) | 0.003 | 1.06 (0.92 to 1.24) | 0.418 | |
| Other government | 1.18 (0.68 to 2.06) | 0.562 | 1.00 (0.47 to 2.11) | 0.989 | |
| Unknown | 3.93 (1.26 to 12.31) | 0.332 | 1.21 (0.73 to 2.01) | 0.465 | |
| Income | ≥$63 333 | 1.0 reference | 1.0 reference | ||
| $50 354–63 332 | 1.05 (0.89 to 1.25) | 0.567 | 0.99 (0.84 to 1.17) | 0.922 | |
| $40 227–50 353 | 1.20 (1.01 to 1.44) | 0.042 | 1.00 (0.84 to 1.20) | 0.985 | |
| <$40 227 | 1.26 (1.02 to 1.57) | 0.034 | 0.95 (0.77 to 1.17) | 0.597 | |
| Unknown | 0.79 (0.34 to 1.87) | 0.019 | -- | ||
| Education (% no HSD) | ≥17.6% | 1.02 (0.81 to 1.28) | 0.875 | 1.03 (0.82 to 1.28) | 0.806 |
| 10.9%–17.5% | 1.07 (0.88 to 1.30) | 0.514 | 1.02 (0.84 to 1.24) | 0.843 | |
| 6.3%–10.8% | 1.21 (1.02 to 1.43) | 0.029 | 1.11 (0.94 to 1.32) | 0.211 | |
| < 6.3% | 1.0 reference | 1.0 reference | |||
| Unknown | 0.44 (0.13 to 1.51) | 0.193 | -- | ||
| Facility type | Community | 1.09 (0.81 to 1.47) | 0.575 | 1.18 (0.87 to 1.61) | 0.284 |
| Comprehensive community | 1.01 (0.89 to 1.15) | 0.897 | 1.10 (0.97 to 1.26) | 0.132 | |
| Academic | 1.0 reference | 1.0 reference | |||
| Integrated network | 1.01 (0.85 to 1.20) | 0.892 | 0.89 (0.75 to 1.05) | 0.154 | |
| Unknown | 3.14 (1.85 to 5.35) | <0.001 | 0.57 (0.14 to 2.33) | 0.432 | |
| AJCC pathological N stage | pN0 | 1.0 reference | 1.0 reference | ||
| pN1 | 1.63 (1.34 to 1.98) | <0.001 | 1.81 (1.53 to 2.13) | <0.001 | |
| pN2 | 2.25 (1.84 to 2.75) | <0.001 | 1.87 (1.59 to 2.20) | <0.001 | |
| AJCC pathological T stage | pT1 | 1.40 (0.69 to 2.83) | 0.350 | 0.72 (0.30 to 1.74) | 0.466 |
| pT1A | 1.0 reference | 1.0 reference | |||
| pT1B | 1.63 (1.40 to 1.91) | <0.001 | 1.62 (1.38 to 1.91) | <0.001 | |
| pT2 | 2.50 (2.06 to 3.05) | <0.001 | 2.08 (1.73 to 2.49) | <0.001 | |
| pT3/3A/3B | 3.43 (2.81 to 4.18) | <0.001 | 2.69 (2.28 to 3.19) | <0.001 | |
| Grade | Well/moderately | 1.0 reference | 1.0 reference | ||
| Poorly/undifferentiated | 2.30 (2.00 to 2.63) | <0.001 | 1.87 (1.47 to 2.38) | <0.001 | |
| Unknown | 1.34 (1.15 to 1.56) | <0.001 | 2.03 (1.58 to 2.62) | <0.001 | |
| Lymph vascular invasion | Not present | 1.0 reference | 1.0 reference | ||
| Present | 1.61 (1.40 to 1.85) | <0.001 | 1.44 (1.26 to 1.66) | <0.001 | |
| Unknown | 0.99 (0.76 to 1.29) | 0.924 | 1.10 (0.87 to 1.40) | 0.417 | |
| Adjuvant chemotherapy | No chemotherapy received | 1.0 reference | 1.0 reference | ||
| Chemotherapy received | 0.78 (0.66 to 0.92) | 0.003 | 0.89 (0.78 to 1.03) | 0.107 | |
| Adjuvant hormone therapy | No hormone therapy received | 1.0 reference | 1.0 reference | ||
| Hormone therapy received | 0.78 (0.40 to 1.50) | 0.451 | 2.12 (1.00 to 4.48) | 0.050 | |
| Unknown | 0.95 (0.64 to 1.41) | 0.787 | 1.11 (0.78 to 1.58) | 0.565 | |
| Adjuvant radiation therapy | No radiation | 1.0 reference | 1.0 reference | ||
| Brachytherapy | 0.85 (0.73 to 0.98) | 0.026 | 0.71 (0.61 to 0.83) | <0.001 | |
| External beam | 0.86 (0.73 to 1.00) | 0.054 | 0.77 (0.67 to 0.89) | <0.001 | |
| Other | 0.64 (0.24 to 1.71) | 0.374 | 0.89 (0.42 to 1.88) | 0.763 | |
*Hazard ratios estimate the risk of an event (death for any cause) in each group compared with that of the reference group. Hazard ratios lower than one represent a risk of events lower than the reference group, whereas hazard ratios higher than one represent a higher risk of events.
AJCC, American Joint Committee on Cancer; HSD, high-school diploma; LN, lymph node; LND, lymphadenectomy; SLN-B, sentinel lymph node biopsy.